Oggolaanshaha FDA ee daawaynta cusub ee ADHD ee dadka waaweyn

Siideynta Xorta ah ee HAYS 5 | eTurboNews | eTN
Written by Linda Hohnholz

Supernus Pharmaceuticals, Inc. ayaa ku dhawaaqday in Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) ay ansixiyeen tilmaame la ballaariyay oo loogu talagalay Qelbree (kaabsoosha la sii daayo viloxazine) ee loogu talagalay daawaynta xanuunka feejignaanta yaraanta (ADHD) ee bukaanka qaangaarka ah ee da'doodu tahay 18 iyo ka weyn. FDA waxay hadda u ogolaatay Qelbree daawaynta ADHD ee carruurta (laga bilaabo da'da 6), dhalinyarada iyo dadka waaweyn.

Ku dhawaad ​​16 milyan oo caruur, dhalinyaro, iyo dad waaweyn ah ayaa qaba ADHD gudaha Maraykanka Halka caruur badan oo qaba ADHD ay ka koraan, ilaa 90% kuwa laga helay ADHD caruurnimadooda waxay sii wadaan inay yeeshaan ADHD qaangaar ahaan.

"Ilaa maanta, fursadaha ADHD aan kicin ee dadka waaweyn aad ayey u xaddidnaayeen," ayuu yiri Greg Mattingly, MD, oo ah aasaasaha iskaashatada St. Charles Psychiatric Associates ee St. Louis, Mo. malaayiin qaangaar ah oo Maraykan ah oo isku dayaya inay helaan daawaynta saxda ah si ay u maareeyaan calaamadaha ADHD."

Qelbree waa dawo cusub oo aan kicinayn oo la qaato hal mar maalintii si loo gaadho maalinta buuxda. Waxtarka iyo hagaajinta calaamadaha ayaa la arkay horaantii daaweynta. Waxay leedahay muuqaal badbaado iyo dulqaad la xaqiijiyay, iyada oo aan lahayn wax caddayn ah oo ku saabsan suurtagalnimada xadgudubka ee daraasadaha kiliinikada. Oggolaanshaha waxay ku salaysan tahay natiijooyin togan oo ka yimid indho-la'aan, labajibbaaran indhoolayaal, kontorool placebo-kontorool ah Wajiga III ee Qelbree ee dadka qaangaarka ah ee qaba ADHD waxayna ka dhigan tahay oggolaanshaha ugu horreeya ee daawaynta cusub ee aan kicin ee dadka waaweyn 20 sano.

"Hogaamiyaha berrinkii CNS, waxaan si buuxda uga go'annahay inaan si wanagsan u fahanno sida loo daweeyo cudurrada kakan sida ADHD," ayuu yiri Jack Khattar, Madaxweynaha iyo Maamulaha Supernus Pharmaceuticals. "Oggolaanshaha maanta waxay calaamad u tahay horumarka weyn ee daaweynta ADHD waana guul muhiim ah hal sano ka dib oggolaanshaha Qelbree si loogu daweeyo bukaannada carruurta. Waxaan ku hanweynahay in aan keenno doorasho cusub oo cusub oo aan kicinayn dadka waaweyn ee suuqa labaatan sano ka dib."

Qiyaasta maalinlaha ah ee dabacsan inta u dhaxaysa 200mg ilaa 600mg, tijaabada Wajiga III waxay la kulantay barta ugu dambeysa ee muujinaysa hoos u dhigista isbeddelka ka yimid saldhigga qiyaasta Baaraha ADHD Adult ADHD (AISRS) wadarta guud ee dhibcaha dhamaadka daraasadda ayaa si weyn ugu weynaa dadka waaweyn lagu daaweeyay Qelbree iyo placebo (p=0.0040). Horumarka la taaban karo ee dhibcaha hoose ee AISRS ee feejignaan la'aanta iyo calaamadaha kacsanaanta / dareenka dareenka ayaa sidoo kale lagu arkay daraasadda. Waxaa intaa dheer, daraasaddu waxay la kulantay barta muhiimka ah ee waxtarka sare ee muhiimka ah ee muhiimka ah ee tirakoobka (p = 0.0023) ee isbeddelka ka soo jeeda asaasiga caalamiga ah ee Clinical Global Impression - Darnaanta Jirrada (CGI-S) ee usbuuca 6. Qiyaasta firfircoon ayaa si fiican loo dulqaatay. Fadlan eeg Macluumaadka Badbaadada Muhiimka ah ee dheeraadka ah ee hoos ku jira.

1 Qelbree waxaa lagu bartay 4 tijaabo oo caafimaad. Mid ka mid ah daraasadda carruurta da'doodu u dhaxayso 6 ilaa 11 da'da, calaamadaha ADHD waxay hoos u dhigeen tirakoobka 100 mg iyo 200 mg doses, laga bilaabo usbuuca 1. Daraasadda dhalinyarada 12 ilaa 17 da'da, calaamadaha ADHD waxay ahaayeen kuwo tirakoob ah. muhiim u ah 400 mg, laga bilaabo usbuuca 2. Daraasada qiyaasta dabacsanaanta ee dadka qaangaarka ah ee 18 ilaa 65 da'da, dhimista dhibcaha calaamadaha ADHD waxay ahaayeen kuwo tirakoob ahaan muhiim u ah bukaanada Qelbree, laga bilaabo usbuuca 2.

MACLUUMAAD BADBAADO BADBAADO

Qelbree waxa laga yaabaa inay kordhiso fikradaha iyo falalka isdilka, carruurta iyo dadka waaweyn ee qaba ADHD, gaar ahaan dhawrka bilood ee ugu horreeya ee daaweynta ama marka qiyaasta la beddelo. U sheeg dhakhtarkaaga haddii aad leedahay (ama haddii ay jirto taariikh qoys) fikrado ama falal is-dilid ka hor inta aanad bilaabin Qelbree. La soco dareenkaaga, dabeecadahaaga, fikradahaaga, iyo dareenkaaga inta lagu jiro daawaynta Qelbree. Isla markiiba ka warbixi isbeddellada cusub ama lama filaanka ah ee calaamadahan. Qelbree waa in aanay qaadan bukaanada qaata dawooyinka niyad-jabka qaarkood, gaar ahaan kuwa loo yaqaanno monoamine oxidase inhibitor ama MAOI, ama dawooyinka neefta qaarkood.

MAXAA LAGU QAADAYAA MAQAALKAN:

  • At a daily flexible-dose between 200mg to 600mg, the Phase III trial met the primary endpoint showing the reduction in the change from baseline of the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score at end of study was statistically significantly greater in adults treated with Qelbree versus placebo (p=0.
  • The approval is based on positive results from a randomized, double blind, placebo-controlled Phase III study of Qelbree in adults with ADHD and represents the first approval of a novel nonstimulant treatment for adults in 20 years.
  • “Today’s approval marks a major advancement in the treatment of ADHD and is an important milestone just one year after the approval of Qelbree to treat pediatric patients.

War ku saabsan qoraaga

Linda Hohnholz

Tafatiraha guud ee eTurboNews ku salaysan eTN HQ.

Rukumo
Ogeysii
martida
0 Comments
Jawaabaha Gudaha ah
Eeg dhammaan faallooyinka
0
Waan jeclaan lahaa fikradahaaga, fadlan faallo ka bixi.x
()
x
La wadaag...